Ptc Therapeutics (PTCT) Capital Leases (2020 - 2025)

Ptc Therapeutics' Capital Leases history runs 6 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• On a quarterly basis, Capital Leases fell 80.74% year-over-year to $3.0 million in Q4 2025; TTM through Dec 2025 was $3.0 million, a 80.74% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, down 80.74% from the prior year.
• Capital Leases slipped to $3.0 million in Q4 2025 per PTCT's latest filing, from $13.8 million in the prior quarter.
• Across five years, Capital Leases topped out at $20.1 million in Q3 2021 and bottomed at $3.0 million in Q4 2025.
• The 5-year median for Capital Leases is $17.2 million (2023), against an average of $16.5 million.
• Across the five-year window, Capital Leases slipped 6.87% in 2022 and slumped 80.74% in 2025, its largest moves.
• Year by year, Capital Leases stood at $20.1 million in 2021, then fell by 6.87% to $18.7 million in 2022, then dropped by 7.98% to $17.2 million in 2023, then retreated by 9.37% to $15.6 million in 2024, then slumped by 80.74% to $3.0 million in 2025.
• Per Business Quant, the three latest PTCT Capital Leases figures stand at $3.0 million (Q4 2025), $13.8 million (Q3 2025), and $13.8 million (Q2 2025).